Khartis Therapeutics, Inc.
Agent50Agent Readiness: 50/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust26Data Trust: 26/100. Bottom 25%. Measured by StartupHub.ai. Median 61.Developing oral small molecule medicines for immunological and chronic diseases.
About
Khartis Therapeutics is a biotechnology company focused on the discovery and development of novel oral small molecule therapies for patients with immune-mediated and chronic inflammatory diseases. The company leverages translational research and scientific innovation to create impactful treatments for significant unmet medical needs in the immunology space. Khartis aims to transition from traditional broad immunosuppression toward more targeted, precision-based oral therapies that offer improved safety and efficacy profiles for chronic conditions.
Key facts
At-a-glance profile data
- Website
- khartistx.com
- Headquarters
- San Diego, United States
- Founded
- 2021
- Total funding
- $50M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 13 Aug 2026 | Series B | $50M | Forge Life Science Partners |
Frequently asked
Is Khartis Therapeutics, Inc. trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Khartis Therapeutics, Inc. is 26 out of 100, based on site security posture and privacy practices.
How much funding has Khartis Therapeutics, Inc. raised?
Khartis Therapeutics, Inc. has raised a total of $50M in funding. The most recent round on record is Series B.
What is Khartis Therapeutics, Inc.'s current status?
Khartis Therapeutics, Inc.'s current operating status is: Inactive.